TUCSON, Ariz., March 24, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Christopher Lunt as its Chief Data and Technology Officer. Lunt is a technology executive with more than 25 years of experience building large-scale data and analytics platforms across the federal government, Silicon Valley, and the healthcare sector. He joins C-Path from the National Institutes of Health (NIH), where he served for 9 years as Chief Technology Officer for the All of Us Research Program. The appointment will strengthen C-Path’s data integration, platform development, and analytics capabilities across its growing portfolio of global collaborations that generate regulatory-grade tools to accelerate drug development across multiple areas.
At the All of Us Research Program, Lunt led the development of a secure, cloud-based research platform that now supports more than 20,000 registered researchers and has produced more than 1,000 peer-reviewed publications. The program has collected genetic, lifestyle, environmental and clinical data from more than 877,000 people thus far with the goal to collect from more than 1 million diverse volunteers across the United States. Before joining the NIH, Lunt served as Vice President of Government Solutions at GetInsured and on appointment to the U.S. Department of Health and Human Services. His background spans venture-capital-backed startups, including an IPO, federal health technology, and international advisory work, including service on the Technology Advisory Board for Our Future Health UK.
“Chris built and led the technology behind one of the most ambitious biomedical data efforts in history, serving thousands of researchers bringing tangible innovation to federal health programs,” said Klaus Romero, M.D., M.S., FCP, Chief Executive Officer of C-Path. “As we expand our data and analytics platform and continue to incorporate AI solutions to accelerate drug development, his track record of delivering secure, accessible infrastructure at scale positions C-Path to deepen the impact of our work.”
“In my career, I’ve seen just how much potential is locked up in health data — and how often that potential goes unrealized because the data remains siloed or difficult to access. When data can’t be brought together and used effectively, it slows our ability to generate the knowledge we need to improve how we develop and deliver care,” said Lunt. “What drew me to C-Path is its long-standing commitment to changing that. For more than two decades, the organization has done the hard work of building trust across sectors and creating the collaborative frameworks that make real data sharing possible. What excites me is the opportunity to build on that foundation with modern, secure, and scalable technology that makes shared data not just accessible, but truly usable. When scientists can work with well-structured, standardized data and get answers in minutes instead of months, it changes the pace of discovery — and ultimately what’s possible for patients and families who are waiting.”
As Chief Data and Technology Officer, Lunt will oversee C-Path’s Data Collaboration Center and the digital infrastructure that supports the organization’s core competencies in regulatory science, quantitative modeling, biomarker development, and clinical outcome assessment. Priorities include advancing the Critical Path Data and Analytics Platform (CP-DAP™), the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), data standardization and interoperability across consortia, and the integration of AI and machine learning capabilities into regulatory-grade drug development tools.
C-Path is entering a period of significant expansion across its data and technology programs, with growing demand for integrated analytics, standardized datasets, and AI-enabled tools across more than a dozen active consortia. With more than 1,600 scientists participating across its programs, C-Path’s ability to convene multistakeholder communities around shared evidence and shared infrastructure positions it to benefit directly from Lunt’s experience building data platforms that serve diverse research communities at scale.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 56% funded by the FDA/HHS, totaling $23,740,424, and 44% funded by non-government source(s), totaling $18,881,611. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
Media Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org
Kissy Black
C-Path
615.310.1894
kblack@c-path.org